These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 12795242)

  • 1. Use of prior information to stabilize a population data analysis.
    Gisleskog PO; Karlsson MO; Beal SL
    J Pharmacokinet Pharmacodyn; 2002 Dec; 29(5-6):473-505. PubMed ID: 12795242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyzing multi-response data using forcing functions.
    Zhang L; Sheiner LB
    J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):283-305. PubMed ID: 16283535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing convergence of Markov chain Monte Carlo simulations in hierarchical Bayesian models for population pharmacokinetics.
    Dodds MG; Vicini P
    Ann Biomed Eng; 2004 Sep; 32(9):1300-13. PubMed ID: 15493516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.
    Proost JH; Schiere S; Eleveld DJ; Wierda JM
    Biopharm Drug Dispos; 2007 Nov; 28(8):455-73. PubMed ID: 17847121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical evaluation of clinical trial design for a population pharmacokinetic study--a case study.
    Nakade S; Nishibori A; Okamoto H; Higuchi S
    Drug Metab Pharmacokinet; 2004 Oct; 19(5):381-9. PubMed ID: 15548850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
    Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
    Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperparameter estimation using stochastic approximation with application to population pharmacokinetics.
    Mentré F; Mallet A; Steimer JL
    Biometrics; 1988 Sep; 44(3):673-83. PubMed ID: 3203126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robust population pharmacokinetic experiment design.
    Dodds MG; Hooker AC; Vicini P
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):33-64. PubMed ID: 16205840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using the time of maximum effect site concentration to combine pharmacokinetics and pharmacodynamics.
    Minto CF; Schnider TW; Gregg KM; Henthorn TK; Shafer SL
    Anesthesiology; 2003 Aug; 99(2):324-33. PubMed ID: 12883405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance comparison of first-order conditional estimation with interaction and Bayesian estimation methods for estimating the population parameters and its distribution from data sets with a low number of subjects.
    Pradhan S; Song B; Lee J; Chae JW; Kim KI; Back HM; Han N; Kwon KI; Yun HY
    BMC Med Res Methodol; 2017 Dec; 17(1):154. PubMed ID: 29191177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of pharmacokinetic parameters by orthogonal regression: comparison of four algorithms.
    Tod M; Aouimer A; Petitjean O
    Comput Methods Programs Biomed; 2002 Jan; 67(1):13-26. PubMed ID: 11750944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Part 2. Development of Enhanced Statistical Methods for Assessing Health Effects Associated with an Unknown Number of Major Sources of Multiple Air Pollutants.
    Park ES; Symanski E; Han D; Spiegelman C
    Res Rep Health Eff Inst; 2015 Jun; (183 Pt 1-2):51-113. PubMed ID: 26333239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacometric estimation methods for aggregate data, including data simulated from other pharmacometric models.
    Välitalo PAJ
    J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):623-638. PubMed ID: 34159497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the performance of FOCE and different expectation-maximization methods in handling complex population physiologically-based pharmacokinetic models.
    Liu X; Wang Y
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):359-70. PubMed ID: 27215925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of point and interval estimates in population pharmacokinetics using NONMEM analysis.
    White DB; Walawander CA; Tung Y; Grasela TH
    J Pharmacokinet Biopharm; 1991 Feb; 19(1):87-112. PubMed ID: 2023111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of population (NONMEM) pharmacokinetic parameter estimates.
    Vozeh S; Maitre PO; Stanski DR
    J Pharmacokinet Biopharm; 1990 Apr; 18(2):161-73. PubMed ID: 2348382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methods of utilizing baseline values for indirect response models.
    Woo S; Pawaskar D; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):381-405. PubMed ID: 19697107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An estimation method of the half-life for a one-compartment model of a single bolus intravenous injection by a single sampling.
    Funatogawa T; Funatogawa I; Yafune A
    J Biopharm Stat; 2007; 17(5):827-37. PubMed ID: 17885868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.